Retatrutide TRIUMPH-2: T2D and Obesity Trial Data
The medical director of a metabolic health clinic gets the same call twice in one week in late 2026: a 52-year-old patient with type 2 diabetes, an A1c of 8.1%, and a BMI of 35 wants to know if the…
Evidence-based articles on weight loss, GLP-1 peptides, nutrition, and metabolic health — organized by topic. Written and reviewed by independent licensed providers.
The medical director of a metabolic health clinic gets the same call twice in one week in late 2026: a 52-year-old patient with type 2 diabetes, an A1c of 8.1%, and a BMI of 35 wants to know if the…
Trial readouts, endpoints, and what the data does — and does not — establish.
The medical director of a metabolic health clinic gets the same call twice in one week in late 2026: a 52-year-old patient with type 2 diabetes, an A1c of 8.1%, and a BMI of 35 wants to know if the…
A 58-year-old patient with a nine-year history of type 2 diabetes, an A1c of 7.8% on metformin and basal insulin, brings a printout from a peptide-research forum to a follow-up visit. The forum…
An endocrinologist at an academic diabetes center described the same conversation recurring roughly twice a month by late 2025: a patient with fifteen or twenty years of type 1 diabetes, an insulin…
A clinic fielding intake calls in early 2024 kept hearing the same question: "Can I just take a pill instead of the shot?" The answer, for the first time with phase 3 data behind it, became more…
A clinic operator running weekly injectable programs gets the same question from three different patients in one afternoon: "What about the one that's supposedly stronger than tirzepatide?" That…
A contract research site running its first peptide-obesity study enrolls 22 subjects, splits them 11 and 11, runs the protocol for 16 weeks, and gets a p-value of 0.11 on the primary endpoint. The…
Head-to-head pharmacology: efficacy, dosing, tolerability, and approval status.
A 52-year-old patient on liraglutide 3.0 mg (Saxenda) for ten months has lost 5% of body weight and plateaued.
A clinic intake coordinator fields the same question three times in one afternoon: a patient has read a press release about a new obesity drug that beat tirzepatide, and wants to know if it's worth…
A patient forwards a supplier's product page advertising a "GLP-3 peptide protocol" and asks a straightforward question: is this the successor to semaglutide, and does the research back it up? The…
A patient walks into a medical weight-loss clinic holding up a phone screen and asks to be switched from semaglutide to "the new GLP-3 shot" she saw discussed in a private Facebook group.
A metabolic clinic that has run weight-management protocols for a few years eventually gets the question from a patient who has been reading peptide forums: "What about the drugs that block…
A clinician fielding a patient's question about "GLP-3 peptide therapy" for metabolic syndrome will not find a corresponding entry in PubMed, ClinicalTrials.gov, or any major endocrinology…
Receptor biology and pharmacokinetics behind the incretin class.
A 52-year-old patient on semaglutide for eighteen months reads the package insert for the first time and finds a boxed warning referencing thyroid C-cell tumors. She calls her prescriber the same…
A clinician reviewing a patient's chart notes something specific: needle aversion documented three visits in a row, an A1c that hasn't moved, and a patient who has asked twice whether there's "a…
A research coordinator running a metabolic-health intake desk fields a version of this question two or three times a month: a patient stalled on semaglutide for eleven weeks asks whether stacking a…
A metabolic clinic running a 240-patient semaglutide titration cohort will, sooner or later, produce a chart that does not make intuitive sense: two patients, matched for starting BMI, age, and…
A clinician fielding intake questions ahead of a GLP-1 prescription hears it more often now: "Is GLP-3 stronger than GLP-1?" or "I saw a research peptide site selling a GLP-3 compound — is that the…
A research team evaluating vendor claims about "GLP-3 receptor binding optimization" for an obesity-focused peptide will not find that receptor described anywhere in the structural biology…
Compound-level profiles across the research-peptide landscape.
A hospital-affiliated endocrinology clinic in Shanghai ran its first formulary review of 2026 with a simple question on the table: which GLP-1 receptor agonist belonged on the preferred list for…
A research team scanning ClinicalTrials.gov for next-generation obesity compounds in 2023 would have found something unusual: a Phase 3 program for a GLP-1/glucagon dual agonist running entirely at…
A patient on a stable GLP-1 regimen for eighteen months hits a weight-loss plateau and a liver panel that still shows elevated ALT despite steady adherence.
A clinic running a research-support line for peptide patients started logging a new pattern in its call notes last quarter: callers asking specifically for "GLP-3 receptor binding agents,"…
A compounding pharmacy processing roughly 300 reconstituted GLP-1 receptor agonist vials a month ran a routine potency check on stock that had been sitting in a standard refrigerator for six weeks.
A compounding pharmacy client once sent over three vials of the same nominal peptide, sourced from three different suppliers, and asked why one batch showed visibly reduced potency in downstream…
Reconstitution, storage, and handling for laboratory research.
A research lab orders a batch of BPC-157 in July. The courier's tracking record shows the package sat on a porch for six hours before pickup confirmation, ambient temperature in the mid-90s…
A research lab logs a batch of results that don't match the prior month's run under an identical protocol. The peptide vial looks the same, the dose calculation checks out on paper, and the…
A research coordinator at a mid-sized peptide research facility reconstituted a lyophilized vial labeled for 5 mg net peptide content with 2 mL of bacteriostatic water instead of the 1 mL specified…
A research team conducting in vitro GLP-1 receptor (GLP-1R) binding assays observes receptor activation values 40–60% below published EC50 benchmarks across three consecutive experiments using a…
Reconstitution diluent selection is one of the more consequential — and most under-documented — decisions in peptide research. The two diluents in widest use, bacteriostatic water for injection…
Adverse-event data, contraindications, and tolerability signals.
In May 2023, Iceland's national medicines agency flagged something unusual in its pharmacovigilance database: a cluster of roughly 150 reports describing suicidal or self-injurious thoughts in…
A 54-year-old patient on semaglutide for eight months presents to an emergency department with epigastric pain radiating to the back. Lipase comes back at four times the upper limit of normal.
A patient returns at week 52 of semaglutide therapy having lost 18% of baseline body weight. The scale result reads as an unambiguous success. The DEXA scan ordered alongside it tells a more…
A 54-year-old patient with type 2 diabetes of 11 years' duration starts tirzepatide for weight management. By week 14, at the 10 mg maintenance dose, she reports bloating, early fullness after a…
A patient presents with an injection-site abscess three weeks into a subcutaneous semaglutide protocol sourced from a state-licensed compounding pharmacy.
The scenario presents itself with increasing frequency in obesity medicine practice: a patient who has completed 36 weeks of tirzepatide (Mounjaro/Zepbound) titration, achieved 10 mg or 15 mg/week…
Regulatory status, shortages, compounding, and the access landscape.
A 68-year-old Medicare Part D enrollee with a BMI of 34, hypertension, and no diabetes diagnosis takes her semaglutide (Wegovy) prescription to the pharmacy and is quoted a cash price near $1,000…
A medical spa running forty semaglutide patients a week out of a strip-mall suite in Scottsdale got a call from its 503B supplier in March 2025: bulk semaglutide vials were being discontinued…
In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win.
Plain-language starting points for the GLP-1 / GLP-3 landscape.
A patient drinks a 75-gram oral glucose solution during a tolerance test and her insulin climbs sharply. A separate protocol gives her an intravenous glucose infusion titrated to produce the exact…
A clinician reviewing a new patient's chart sees semaglutide 2.4 mg listed alongside a second injectable, cagrilintide, and the obvious question comes up: isn't this redundant? Two drugs for the…
Clinical evidence and mechanism of action for GLP-1 and GLP-3 weight-loss therapies, sourced from peer-reviewed trials and medical literature.
An introduction to GLP3 Weight Loss as an independent educational resource and research-product catalog — what we are, what we are not, and how we connect readers with independent licensed providers.
A practical, evidence-based primer on GLP-1 weight-loss therapy — how the peptides are studied, expected results in trials, and how the research is read.
How GLP3 Weight Loss works as an independent information and research-product resource — our evidence-first approach and our referral model to independent licensed providers.